Dishman Carbogen Amcis Set for Q2 After ₹57.88 Crore Loss

Dishman Carbogen Amcis Limited is scheduled to report Q2 FY27 results on November 13, 2026, following a consolidated net loss of ₹57.88 crore in Q1 FY27 and revenue from operations of ₹677.64 crore. The September-quarter filing is important because it will indicate whether the June-quarter loss reflected timing issues or a more sustained operational weakness.

When will Dishman Carbogen Amcis report its Q2 FY27 results?

Dishman Carbogen Amcis is scheduled to announce its Q2 FY27 results on November 13, 2026, for the quarter from July 1, 2026 to September 30, 2026. The company has also announced a conference call at 3:00 pm IST on November 16, 2026 to discuss the quarterly and half-year financial performance with investors.

The scheduled reporting date comes close to the regulatory deadline for September-quarter results. Indian listing rules require listed companies to publish quarterly results within 45 days of the quarter end, placing the outer deadline for the September 2026 quarter on November 14, 2026.

Earlier information had indicated that a board-meeting intimation was not available with the NSE or BSE as of September 10, 2026. The subsequent announcement of a November 13 result date and a November 16 conference call gives investors a defined timetable for the financial update.

What happened in Dishman Carbogen's June 2026 quarter?

Dishman Carbogen reported a consolidated net loss of ₹57.88 crore for the quarter ended June 2026, compared with a net profit of ₹23.41 crore in the corresponding quarter a year earlier. Revenue from operations declined 4.29% year on year to ₹677.64 crore from ₹708.05 crore.

Another reported comparison places Q1 FY27 revenue at about ₹678 crore, against roughly ₹653 crore in the September 2025 quarter. The reported June-quarter loss followed a profit of ₹65 crore in the September 2025 quarter, creating a demanding comparison point for the upcoming September 2026 result.

The available data also indicates that June-quarter consolidated revenue declined on a sequential basis. That movement, together with the shift from profit to loss, places attention on the pace of recovery in the company's contract development and manufacturing operations and on the cost base reflected in consolidated earnings.

What will investors examine in the September-quarter filing?

Investors will examine whether Dishman Carbogen returns to profitability and whether revenue holds near or exceeds the ₹700 crore level referenced in market commentary. No verified analyst consensus estimate for the company was available in the supplied information, so any numerical forecast should be treated cautiously.

Market commentary has identified four operational indicators: the direction of consolidated revenue, EBITDA margin, management's assessment of second-half execution, and cash-flow performance following a ₹128 crore debt raise. These are not company guidance or verified outcome estimates. They are areas that may help readers assess the reasons behind the Q1 performance and management's current operating outlook.

The company operates through an India entity that has been associated with management guidance of 30% to 35% growth for FY27. At the consolidated level, however, the supplied material notes that legacy Western pharmaceutical-services operations could moderate the overall performance. The Q2 disclosures and conference call will be relevant for understanding the relative contribution of these businesses.

How does the Q2 result matter for shareholders and the life-sciences sector?

The Q2 filing matters for shareholders because it follows a quarterly loss, lower year-on-year sales, and a reported sequential revenue decline. A clear reconciliation of revenue, margins, financing and cash flow would provide a more complete basis for assessing the June-quarter result than revenue alone.

For the broader Indian life-sciences sector, the figures will be viewed against industry valuation and growth comparisons cited in the available material. The average trailing price-to-earnings ratio for the Indian life-sciences industry was stated at 42 times, while Dishman Carbogen's revenue is forecast to grow 17% over the next year versus an industry growth forecast of 38%.

Those industry forecasts are comparative estimates rather than reported company performance. They nevertheless show why investors may focus on execution in the India business, progress in pharmaceutical-services demand and the company's ability to convert operational activity into consolidated profits.

What should investors listen for on the November 16 call?

Investors should listen for management's explanation of the June-quarter loss, the status of project schedules, and any comments on demand across its businesses. Commentary on whether project deferrals have continued, as referenced in market commentary, would be relevant to evaluating the near-term revenue trend.

The call may also provide context on the ₹128 crore debt raise and the company's cash-flow position. Details on working capital, capital expenditure, operating margins and the outlook for the second half of FY27 would help investors compare management's discussion with the reported September-quarter numbers.

Conclusion

Dishman Carbogen's Q2 FY27 result is a significant update after the company posted a ₹57.88 crore consolidated loss in the June 2026 quarter and revenue of ₹677.64 crore, down 4.29% year on year. The September-quarter numbers will be measured against the ₹653 crore revenue and ₹65 crore profit reported in the September 2025 quarter.

The next disclosed event is the November 16, 2026 conference call at 3:00 pm IST. Investors will watch for management's comments on second-half execution, project timing, the India entity's FY27 growth guidance, margins and cash flow after the debt raise.